An Open-Label, Long Term, Safety, and Tolerability Study of VEGF Trap in Patients With Incurable, Relapsed or Refractory Solid Tumors or Lymphoma
OBJECTIVES:
- Determine the long-term safety and tolerability of VEGF Trap in patients with incurable
relapsed or refractory solid tumors or non-Hodgkin's lymphoma with stable or responding
disease after receiving treatment on protocol MSKCC-01131.
- Determine the biological effect of this therapy on suppressing tumor growth or
progression in these patients.
- Determine the steady state concentration of VEGF Trap over time in these patients.
- Determine whether patients develop antibodies to this therapy during extended exposure.
OUTLINE: This is an extension study for patients who showed evidence of stable disease or
complete or partial remission after completing treatment on protocol MSKCC-01131.
Patients continue to receive VEGF Trap subcutaneously once weekly for up to an additional 6
months in the absence of unacceptable toxicity. Patients receive treatment at the same dose
level as on protocol MSKCC-01131.
Patients are followed at approximately 30 days.
PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Treatment
Jakob Dupont, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
REGENERON-VGF-ST-0105
NCT00045266
April 2002
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |